Strides Pharma receives regulatory approval to conduct trials in India for potential COVID-19 drug

Indian pharmaceutical company Strides Pharma Science Ltd said on Thursday it has got regulatory approval to conduct clinical trials of antiviral drug favipiravir, considered a potential treatment for COVID-19

Reuters May 21, 2020 11:52:23 IST
Strides Pharma receives regulatory approval to conduct trials in India for potential COVID-19 drug

Bengaluru: Indian pharmaceutical company Strides Pharma Science Ltd said on Thursday it has got regulatory approval to conduct clinical trials of antiviral drug favipiravir, considered a potential treatment for COVID-19.

The Bengaluru-based company has received approval from the Drug Controller General of India (DCGI) to conduct trials of favipiravir in the country, Strides Founder and Non-Executive Chairman Arun Kumar said on a post-earnings conference call, without giving any more details.

Strides’ announcement comes after Glenmark Pharmaceuticals Ltd said last month it became the first pharma company in the country to get the nod to conduct favipiravir trials.

Click here to follow LIVE updates on coronavirus outbreak

The Mumbai-based company has initiated late-stage clinical trials and expects study results by July or August.

Favipiravir is manufactured under the brand name Avigan by a unit of Japan’s Fujifilm Holdings Corp and was approved for use as an anti-flu drug in the country in 2014.

Click here to follow LIVE news and updates on stock markets

However, on Wednesday, Kyodo News reported that so far there has been no clear evidence of efficacy for Avigan in treating the novel coronavirus in some clinical trials.

Strides late on Wednesday posted a fourth-quarter consolidated net loss of 2.07 billion rupees ($27.35 million), as it booked a 1.13 billion rupees write-down of inventory and other expenses related to withdrawal of ranitidine products.

The company’s shares rose as much as 5.3 percent to a two-week high in early trade, but pared some gains and were last up 1.8 percent at 0430 GMT.

Updated Date:

also read

India sees 17,073 new COVID-19 cases, 21 deaths in last 24 hours, positivity rate jumps to 5.62%
India

India sees 17,073 new COVID-19 cases, 21 deaths in last 24 hours, positivity rate jumps to 5.62%

The fresh COVID-19 infections reported today are 45.43 per cent higher than the daily cases on Sunday. Maharashtra alone logged 6,493 new cases of COVID-19 and five deaths in the last 24 hours

India records 11,793 new COVID-19 infections, 27 deaths in last 24 hours; active case count rises to 96,700
India

India records 11,793 new COVID-19 infections, 27 deaths in last 24 hours; active case count rises to 96,700

According to health ministry, 9,486 patients recuperated from coronavirus in the last 24 hours, increasing the total recoveries to 4,27,97,092. The national recovery rate currently stands at 98.57 per cent

India reports 13,313 new COVID-19 cases, 38 deaths in last 24 hours
India

India reports 13,313 new COVID-19 cases, 38 deaths in last 24 hours

India now has 83,990 active infections of COVID-19. There has been increase of 2,303 cases in just 24 hours and the active caseload now stands at 0.19 per cent of total cases